Provided by Tiger Trade Technology Pte. Ltd.

BIODLINK-B

4.020
0.000
Volume:553.60K
Turnover:2.22M
Market Cap:3.11B
PE:-24.89
High:4.080
Open:4.080
Low:3.970
Close:4.020
52wk High:5.870
52wk Low:1.700
Shares:773.00M
HK Float Shares:772.79M
Volume Ratio:0.45
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.161
ROE:-14.81%
ROA:-3.63%
PB:4.26
PE(LYR):-24.89
PS:3.56

Loading ...

BIODLINK Convenes 11 June 2026 EGM to Approve CDMO Master Services Agreement with WuXi XDC

Bulletin Express
·
May 26

BioDlink shareholders vote June 11 on WuXi XDC CDMO services pact with RMB 424.8 million 2028 cap

Reuters
·
May 26

BioDlink Reports No Share Capital Changes in April; 7.61 Million Pre-IPO Options Cancelled

Bulletin Express
·
May 07

BIODLINK-B Shares Surge Over 9% Following Appointment of WUXI XDC CEO to Key Roles

Stock News
·
Apr 29

BRIEF-Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson

Reuters
·
Apr 28

BioDlink Announces Comprehensive Board Reshuffle Following WuXi XDC Take-Over

Bulletin Express
·
Apr 28

BIODLINK-B (01875) Appoints Dr. Li Jincai as Executive Director and Board Chairman

Stock News
·
Apr 28

Biodlink International Co Ltd - Mr. Shan Fu Resigns as Executive Director and Chairperson of Board

THOMSON REUTERS
·
Apr 28

Biodlink International Co Ltd - Appoints DR. Jincai Li as Executive Director and Chairperson of Board

THOMSON REUTERS
·
Apr 28

BIODLINK-B 2025年业绩:营收7.48亿元同比下降32%,CDMO业务稳健增长,拟引入战略并购

Bulletin Express
·
Apr 28

TOT BIOPHARM publishes 2025 annual report

Reuters
·
Apr 28

BioDlink Keeps Share Capital Steady at 772.79 Million; Confirms Public Float Compliance in March 2026

Bulletin Express
·
Apr 09

Stock Track | BIODLINK-B Soars 11.09% Intraday as WUXI XDC Takeover Becomes Effective

Stock Track
·
Mar 20

BIODLINK-B Surges Over 11% Again, Shares Double This Year as WUXI XDC Takeover Becomes Effective

Stock News
·
Mar 20

BioDlink International (SEHK:1875) Small FY 2025 H1 Profit Tests Bearish Loss Narratives

Simply Wall St.
·
Mar 19

BIODLINK-B Surges Over 9% as WUXI XDC's Takeover Offer Becomes Effective

Stock News
·
Mar 19

Corrected-Biodlink International (Not TOT BIOPHARM International) FY Revenue RMB 747.645 Million

THOMSON REUTERS
·
Mar 18

BIODLINK-B Reports Annual Revenue of RMB 748 Million, Highlighting Strategic Shift to CDMO

Stock News
·
Mar 18

TOT BIOPHARM International FY Net Income Attributable RMB -100.4 Million

THOMSON REUTERS
·
Mar 18

WuXi XDC (02268) Gains Control of 60% Voting Rights in BioDlink-B (01875); Voluntary Cash Offers Declared Unconditional

Bulletin Express
·
Mar 17